Please login to the form below

Not currently logged in
Email:
Password:

GSK appoints Heineken and Shell director Hans Wijers to board

Is also chair designate of the brewery firm

Hans Wijers, GSKChairman designate of brewery firm Heineken, Hans Wijers, has been appointed to the board of GlaxoSmithKline (GSK).

Wijers, who is also a non-executive director at Heineken and deputy chair at oil company Shell, will assume his GSK role from April 1, 2013, subject to shareholder approval at GSK's next annual general meeting.

Although lacking direct experience in healthcare, Wijers has a very rich history in business, having previously served as CEO and chair of paint and chemicals company AkzoNobel in addition to his current board roles.

He also has experience in politics, having served as minister for economic affairs in the Netherlands from 1994 to 1998.

GSK's chair Sir Christopher Ghent said: “I am delighted to welcome Hans to the Board. His broad business experience, including as chief executive of AkzoNobel, together with his economic and political knowledge will enable him to make a significant contribution to the future success of GSK.”

Wijers joins a list of board members from outside healthcare that includes economist and former CEO of mining company Rio Tinto Sir Robert Wilsom; JP Morgan's Jing Ulrich; and Stacey Cartwright, who is chief financial officer at fashion firm Burberry.

28th January 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics